Article
Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): monocentric study.
Cancer chemotherapy and pharmacology - 1 Apr 2017
Tandia Mahamadou, Mhiri Asma, Paule Bernard, Saffroy Raphaël, Cailliez Valérie, Noé Gaëlle, Farinotti Robert, Bonhomme-Faivre Laurence
Abstract excerpt
OBJECTIVES: We studied the relation between the polymorphism of P-glycoprotein (P-gp) and of breast cancer resistance protein (BCRP), encoded by ABCB1 and ABCG2 genes, respectively, and the pharmacokinetic variability and clinical response during the treatment with sorafenib of hepatocellular carcinoma. METHODS: At the Paul Brousse Hospital in Villejuif, France, 47 consecutive patients with advanced HCC treated...
Topics
Join the communities discussing this publication.
